The Parkinson Cannabinoid Trial Measured Motor Function in the Best Medication ON State
The Parkinson trial assessed motor function while usual Parkinson medicines were working optimally. It did not test cannabinoids as a substitute for those medicines or establish an OFF-state benefit.
The protocol retained usual treatment
Anti-Parkinson medication was kept constant, and motor MDS-UPDRS testing was conducted in the best ON state. Eligibility required sufficient residual motor symptoms under that condition. The comparison therefore concerned an added cannabinoid preparation in people receiving their usual care.
ON-state and OFF-state questions are different
A treatment might affect residual symptoms under stable medication differently from symptoms after medication withdrawal or during wearing-off. This trial did not independently establish all those responses. A null result in the tested state should not be relabeled as a measured result in an untested state.
The primary comparison remained nonsignificant
The CBD/THC group did not improve significantly more than placebo on the main motor endpoint. Within-group improvement did not establish a replacement strategy or reduced need for standard treatment. A scientific interpretation should retain the assessment state and continuing medication context alongside the result. Those conditions are part of the evidence, rather than optional details that can be dropped when applying the finding elsewhere.
Related analysis: the study’s broader findings and limitations.
